Covalon Technologies (COV) AI Stock Analysis

• Market Cap: C$47.23M
• Dividend Yield: N/A
• Average Volume (3M): 17.17K
• Price to Earnings (P/E): 95.7
• Beta (1Y): 0.12
• Revenue Growth: 5.29%
• EPS Growth: -29.02%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 27,618,076
• 10 Day Avg. Volume: 12,083
• 30 Day Avg. Volume: 17,167
• PEG Ratio: -0.88
• Price to Book (P/B): 1.87
• Price to Sales (P/S): 1.75
• P/FCF Ratio: 34.99
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.12
• Revenue Forecast (FY): C$38.40M

• Rating: 62 Neutral
• Price Target: C$2.00 ▲(14.29% Upside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

The score is primarily supported by improved profitability versus 2022–2023 and strong TTM cash generation alongside low leverage. It is held back by the recent TTM margin and revenue step-down and a high P/E (~51), while technicals are mixed (shorter-term strength but still below the 200-day trend with slightly negative MACD).

Positive Factors

Strong trailing cash generation

Sustained positive TTM operating and free cash flow provides durable internal funding for R&D, working capital and distribution expansion. Strong FCF relative to earnings supports reinvestment and resilience versus one-time shocks, improving long-term self‑funding capacity.

Conservative balance sheet / low leverage

Very low leverage gives the company financial flexibility to invest in product development and absorb operational variability. A conservative balance sheet reduces refinancing risk, supports longer product adoption cycles and preserves capacity to fund strategic initiatives.

Recurring consumable product model with solid gross margins

A consumables-focused business tied to clinical workflows creates repeat demand and predictable unit volumes. Coupled with maintained gross margins above 50%, this structure supports steady cash conversion and scalability of operating leverage as volumes recover or expand.

Negative Factors

TTM revenue decline and margin compression

A declining run-rate and compressed operating margins reduce durable profitability and limit reinvestment capacity. If the TTM step-down persists, it raises execution risk for sustaining product adoption and could force either cost cuts that impair growth or higher investment that pressures cash flow.

Historically choppy cash flows

Prior multi-year periods of negative cash flow indicate operational sensitivity to volume or pricing shifts. This volatility makes long-term planning harder, increases the need for liquidity buffers, and raises the chance that a future downturn could force dilutive financing or cutbacks.

Modest returns on equity

Mid-single-digit ROE signals limited capital efficiency and modest ability to convert profits into shareholder value. Over time, low ROE constrains organic growth funding and may require the firm to pursue costlier external capital or slower expansion to meet strategic objectives.

Covalon Technologies Business Overview & Revenue Model

Company Description

Covalon Technologies Ltd. researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, Europe, the Middle East, Asia, Latin America, and internationally. The company has 3 proprietary platform technologies, including collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; antimicrobial silicone adhesive platform that is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity; and medical coating platform, a proprietary process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. Its products include wound care dressings; surgical and peri-operative products; and infection management products. The company offers its products under the Covalon brand name through third-party distribution networks and company's direct sales force. It serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. The company is headquartered in Mississauga, Canada.

How the Company Makes Money

Covalon makes money primarily by selling its medical consumable products to healthcare providers and through distribution partners. Its revenue model is largely product-based and recurring in nature because many of its items (e.g., dressings, antimicrobial barriers, and related infection-prevention supplies) are single-use or regularly replaced in clinical workflows. Key revenue streams include (1) advanced wound care product sales and (2) infection prevention product sales used in acute-care settings. The company generates revenue across geographies by supplying hospitals and healthcare systems either directly or via third-party distributors, with earnings influenced by adoption within hospital protocols, purchasing contracts, and ongoing clinical utilization of its consumable product portfolio. Specific partnership details and revenue breakdowns by product line: null.

Covalon Technologies Financial Statement Overview

Summary

Improved materially from 2022–2023 losses to profitability in 2024–2025, with strong TTM operating cash flow and free cash flow. Offsetting this, the TTM run-rate weakened (revenue down ~3.9%) and margins compressed meaningfully versus FY2025, indicating higher execution risk if the slowdown persists.

Income Statement

Profitability has improved materially versus 2022–2023 (when losses were substantial), with the business returning to positive earnings in 2024 and remaining profitable in 2025. However, the most recent TTM (Trailing-Twelve-Months) shows a meaningful step-down in profitability versus FY2025 (annual): net margin fell to ~3.1% from ~6.3% and operating margin compressed to ~1.6% from ~6.3%. Revenue is also slightly down in the TTM period (about -3.9%), suggesting the current run-rate is weaker even though gross margin remains solid (~51–53%).

Balance Sheet

The balance sheet looks conservatively financed with low leverage: debt is modest relative to equity (debt-to-equity ~0.07–0.08 in recent periods, and even lower in FY2024). Equity is sizable versus total assets, which provides a cushion for a biotech business that can face volatility. Returns on equity have normalized to mid-single-digits in FY2024–FY2025 and TTM after being sharply negative in 2022–2023, but the recent profitability dip in TTM could pressure returns if it persists.

Cash Flow

Cash generation is a key strength in the latest period: TTM (Trailing-Twelve-Months) operating cash flow (~$7.9M) and free cash flow (~$6.7M) are strong relative to net income, and free cash flow growth is sharply positive. That said, cash flow has been choppy over the cycle (negative operating/free cash flow in 2022–2023 and a softer FY2025 annual operating cash flow compared with earnings), so sustainability depends on maintaining the improved cash conversion seen in TTM.

Breakdown	TTM	Sep 2025	Dec 2024	Dec 2023	Dec 2022	Sep 2021
Income Statement
Total Revenue	31.54M	32.82M	31.17M	26.60M	18.15M	19.56M
Gross Profit	16.28M	17.47M	18.93M	14.36M	7.49M	9.70M
EBITDA	1.44M	3.01M	3.14M	-3.56M	-8.11M	1.54M
Net Income	977.42K	2.06M	2.67M	-4.46M	-9.66M	23.48M
Balance Sheet
Total Assets	32.80M	36.12M	31.81M	24.90M	30.38M	40.58M
Cash, Cash Equivalents and Short-Term Investments	17.88M	17.37M	16.75M	8.79M	14.06M	22.95M
Total Debt	2.07M	2.25M	901.67K	1.56M	2.17M	2.59M
Total Liabilities	6.41M	5.40M	4.30M	6.11M	6.15M	7.21M
Stockholders Equity	26.39M	30.73M	27.50M	18.79M	24.23M	33.37M
Cash Flow
Free Cash Flow	6.68M	1.65M	3.06M	-4.50M	-9.08M	443.71K
Operating Cash Flow	7.92M	2.29M	3.47M	-3.18M	-7.99M	621.37K
Investing Cash Flow	-1.37M	-847.02K	-281.63K	-81.02K	-843.02K	-278.53K
Financing Cash Flow	-4.74M	-529.35K	4.97M	-2.16M	-2.19M	-8.25M

Covalon Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:COV, the sentiment is Negative. The current price of 1.75 is below the 20-day moving average (MA) of 1.79, above the 50-day MA of 1.72, and below the 200-day MA of 2.01, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 45.31 is Neutral, neither overbought nor oversold. The STOCH value of 11.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:COV.

Covalon Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COV	62 Neutral	C$47.23M	95.68	3.31%	―	5.29%	-29.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SVA	47 Neutral	C$52.16M	-5.76	―	―	―	54.38%
DTC	45 Neutral	C$32.70M	-6.55	―	―	―	72.92%
MDNA	42 Neutral	C$48.11M	-4.40	-103.51%	―	―	54.74%
MIR	42 Neutral	C$47.72M	-17.16	―	―	-41.70%	-35.42%

Covalon Technologies Corporate Events

Covalon Sets Virtual-Only Annual Shareholder Meeting for March 25, 2026

Covalon Technologies plans to hold its annual meeting of shareholders on March 25, 2026, at 2:00 p.m. Eastern Time in a virtual-only format accessible via live webcast. The event will feature a presentation by CEO Brent Ashton followed by a question-and-answer session, providing shareholders with direct insight into the company’s strategic direction.

Registered and non-registered shareholders will be able to participate online, with specific procedures in place for voting and appointing proxyholders through TSX Trust’s virtual meeting platform. The company has also made its management information circular, financial statements, and MD&A available through regulatory and corporate channels, underscoring its focus on transparency and shareholder engagement ahead of the meeting.

The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.00 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.

Covalon Sets Virtual-Only Annual Shareholder Meeting for March 25, 2026

Covalon Technologies will hold its annual shareholder meeting on March 25, 2026, at 2:00 p.m. Eastern Time in a virtual-only format, allowing shareholders to attend and vote online via live webcast. The event will feature a presentation from CEO Brent Ashton followed by a Q&A session, with detailed instructions provided for registered and non-registered shareholders, proxyholders, and guests, underscoring the company’s push for accessible and broad investor participation.

Shareholders must complete specific proxy appointment and registration steps with TSX Trust to vote online, while non-registered holders who do not appoint themselves as proxyholders may attend only as guests. The company has also directed investors to its management information circular, financial statements, and MD&A available on SEDAR+ and its website, reinforcing transparency and ongoing engagement with its investor base ahead of the meeting.

The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.00 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.

Covalon Posts Near Break-Even Q1 as Clinical Wins and U.S. Contracts Bolster 2026 Outlook

Covalon reported essentially break-even results for its fiscal 2026 first quarter, as revenue declined to $6.9 million from $8.1 million a year earlier and net income fell to $0.1 million, reflecting variability in order timing but supported by a strong balance sheet with $17.9 million in cash and no debt. Management highlighted that sales and orders in early Q2 have already surpassed total Q1 revenue and pointed to accelerating clinical validation, new marquee customers, major U.S. network approvals, and a Vizient-linked contract via partner HARTMANN USA as catalysts that could strengthen growth, enhance industry positioning, and open doors to strategic transactions such as partnerships or M&A.

The company also emphasized growing clinical recognition of its VALGuard vascular access line guard, including peer-reviewed data from a leading U.S. pediatric hospital showing significant reductions in bloodstream infections, which is driving increased customer interest. Educational efforts with vascular access expert Dr. Nancy Moureau and collaborations with professional associations are further elevating awareness of IV line contamination and infection risks, reinforcing Covalon’s role in patient safety solutions and potentially deepening its penetration into large healthcare systems.

The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.00 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.

Covalon Partners with AVA and Dr. Nancy Moureau on IV Infection Prevention Webinar

Covalon Technologies is partnering with the Association for Vascular Access and noted vascular access expert Dr. Nancy Moureau on a continuing education webinar addressing IV line contamination and its role in catheter-associated bloodstream infections. By supporting this accredited training initiative, Covalon seeks to advance evidence-based vascular access practices, reinforcing its positioning as a patient-safety-focused MedTech player and potentially deepening its engagement with clinicians and healthcare institutions.

The webinar, hosted by AVA and led by Dr. Moureau, will explore practical, easy-to-implement interventions to close gaps in infection prevention and improve IV therapy outcomes. This collaboration underscores growing industry emphasis on reducing life-threatening complications from IV therapy, which could bolster adoption of Covalon’s infection-prevention solutions and strengthen its relationships with key stakeholders in the vascular access community.

The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.00 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.

Covalon Sets February 25 Call to Review Q1 Fiscal 2026 Results

Covalon Technologies said it will release its first-quarter fiscal 2026 results before markets open on February 25, 2026, and will host a conference call and webcast at 8:30 a.m. ET the same day to discuss the financial performance. The company will provide a replay of the call on its website and make related financial statements and management discussion documents available through its investor channels, giving stakeholders structured access to its latest financial and operational updates.

The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.00 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.

Covalon Sets Date and Call for Q1 Fiscal 2026 Results

Covalon Technologies plans to release its first-quarter fiscal 2026 results on February 25, 2026, before the market opens and will host a conference call and webcast the same morning to discuss the figures and take questions from participants. The company will also make a recording of the call and related financial documents available to investors online, underscoring its efforts to maintain transparency and engagement with shareholders as it advances its position in the medical technology sector.

The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.00 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.